Vnitr Lek 2007, 53(10):1114-1118

The benefit from ibandronate in the treatment of postmenopausal osteoporosis

Z. Málek
Osteocentrum MEDIEKOS Labor s.r.o. Zlín, ředitel MUDr. Pavel Novosad

Apart from other factors, the treatment of osteoporosis is limited by a narrow range of applicable drugs. Ibandronate, forming part of the aminobisphosphonate group, which was launched in clinical practice in 2005, has extended the range of treatment options. It allows for intermittent dosage in 1-month (oral form) or 3-month (intravenous form) intervals, whilst the high efficiency of treatment and good safety profile are preserved. Intermittent dosage significantly improves the adherence of patients to treatment, which has, apart from other advantages, a positive effect on cost efficiency of treatment. In addition, oscillation in bone remodelation in the course of intermittent ibandronate treatment might have a positive effect on the physiology of bone tissue, thus reducing some risks associated with bisphosphonate treatment.

Keywords: osteoporosis; ibandronate; bone remodelation; osteoporotic fracture

Received: September 20, 2007; Accepted: October 3, 2007; Published: October 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Málek Z. The benefit from ibandronate in the treatment of postmenopausal osteoporosis. Vnitr Lek. 2007;53(10):1114-1118.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Dennison E, Cooper C. Epidemiology of osteoporotic fractures. Hormonal Research 2000; 54(Suppl 1): 58-63. Go to original source... Go to PubMed...
    2. Kanis JA, Johnell O, Oden A et al. Long-term risk of osteoporotic fracture in Malmö. Osteoporos Int 2000; 11: 669-674. Go to original source... Go to PubMed...
    3. Kanis JA, Johnell O. Requirements for DXA for the management of osteoporosis in Europe. Osteoporosis Int 2005; 16: 229-238. Go to original source... Go to PubMed...
    4. Cummings SR, Black DM, Thompson DE et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280: 77-82. Go to original source... Go to PubMed...
    5. Pols HA, Felsenberg D, Hanley DA et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Foxamax International Trial Study Group. Osteoporos Int 1999; 9: 461-468. Go to original source... Go to PubMed...
    6. Harris ST, Watts NB, Genant HK et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999; 282: 1344-1352. Go to original source... Go to PubMed...
    7. Caro J, Isak KJ, Huybrechts KF. Clinical and economic impact of adherence to osteoporosis medication (abstract PL6). Osteoporos Int 2003; 14(Suppl 7): S2-S3.
    8. Tosteson AN, Grove MR, Hammond CS et al. Early discontinuation of treatment for osteoporosis. Am J Med 2003; 115: 209-216. Go to original source... Go to PubMed...
    9. Rizzoli R, Greenspan SL, Bone G 3rd et al. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 2002; 17: 1988-1996. Go to original source... Go to PubMed...
    10. Leu CT, Luegmayr E, Freedman LP et al. Relatice binding affinities of bisphosponates for human bone. Bone 2004; 34(Suppl 1): S62.
    11. Green JT. Bisphoshponates: preclinical review. Onkologist 2004; 9(Suppl 4): 3-13. Go to original source... Go to PubMed...
    12. Epstein S, Zaidi M. Biological properties and mechanism of action of ibandronate: Application to the treatment of osteoporosis. Bone 2005; 37: 433-440. Go to original source... Go to PubMed...
    13. Frith JC, Monkkonen J, Blackburn GM et al. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosin 5'-(beta;, γ-dichlormetylen) tripohosphate, by mammalian cells in vitro. J Bone Miner Res 1997; 12: 1358-1367. Go to original source... Go to PubMed...
    14. Borah B, Dufresne TE, Chmielewski PA et al. Risedronate preserves bone architecture in postmenopauzal woman with osteoporosis as measured by tree-dimensional microcomputed tomography. Bone 2004; 34; 736-746. Go to original source... Go to PubMed...
    15. Štěpán J, Michalská D, Vokrouhlická J. Sustained suppression by 50% below premenopausal levels of the marker of bone formation (PINP) in postmenopausal women treated with alendronate. Osteoporos Int 2002; 13(Suppl 1): S20.
    16. Odvina CV, Zerwekh JE, Rao DS et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005; 90: 1294-1301. Go to original source... Go to PubMed...
    17. Richer E, Lewis MA, Odvina CV et al. Reduction in normalized bone elasticity following long-term bisphosphonate treatment as measured by ultrasound critical angle reflectometry. Osteoporos Int 2005; 16: 1384-1392. Go to original source... Go to PubMed...
    18. Chesnut CH 3rd, Skag A, Christiansen C et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19: 1241-1249. Go to original source... Go to PubMed...
    19. Miller PD, McClung MR, Macovei L et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE Study. J Bone Miner Res 2005; 20: 1315-1322. Go to original source... Go to PubMed...
    20. Emkey R, Zaidi M, Lewiecki M et al. Two-year efficacy and tolerability of intermittent intravenous ibandronate injections in postmenopausal osteoporosis: the DIVA study. In: American College of Rheumatology, 69th Annual Scientific Meeting; 2005; San Diego 2005.
    21. Miller PD, Zerbini CAF, Recker RR et al. Clinical comparison in BMD gains with monthly oral ibandronate (150 mg) and weekly oral alendronate (70 mg): results from the MOTION study ABSMR 2007 (poster).
    22. Delmas PD, Lewiecki EM, Ragi-Eis S et al. The MOTION study: tolerability of monthly ibandronate and weekly alendronate in women with postmenopausal osteoporosis ABSMR 2007 (poster).
    23. Emkey R. Patient preference for once-monthly ibandronate versus once weekly alendronate in a randomized, open-label, cross over trial: the Bonviva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 2005; 21: 1895-1903. Go to original source... Go to PubMed...
    24. Cooper A, Drake J, Brankin E. Treatment persistence with once-monthly ibandronate and patient support vs once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 2006; 60: 896-905 Go to original source... Go to PubMed...
    25. Stakkestad JA, Benevolenskaya LI, Štěpán JJ et al. Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women. Ann Rheum Dis 2003; 62: 969-975. Go to original source... Go to PubMed...
    26. Zaidi M, Epstein S, Friend K. Modeling of serum C-telopeptide levels with daily and monthly oral ibandronate in humans. Ann N Y Acad Sci 2006; 1068: 560-563. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.